
Lipiodol (Ethiodized Oil) Injection Indication in HCC Patients
Lipiodol® is indicated for selective hepatic intra-arterial use for imaging tumors in adults with known HCC.
WARNING: FOR INTRALYMPHATIC, INTRAUTERINE AND SELECTIVE HEPATIC INTRA-ARTERIAL USE ONLY See Full Prescribing Information for complete Boxed Warning. Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of Lipiodol. Inject Lipiodol slowly with radiologic monitoring; do not exceed recommended dose. |
The American Cancer Society’s estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2020 are:
Lipiodol® is indicated for selective hepatic intra-arterial use for imaging tumors in adults with known HCC.
Lipiodol® (Ethiodized Oil) Injection - Imaging Tumors in Adults with Known HCC Brochure
WARNING: FOR INTRALYMPHATIC, INTRAUTERINE AND SELECTIVE HEPATIC INTRA-ARTERIAL USE ONLY See Full Prescribing Information for complete Boxed Warning. Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of Lipiodol. Inject Lipiodol slowly with radiologic monitoring; do not exceed recommended dose. |
Indication and Usage
LIPIODOL® (ethiodized oil) injection is a prescription oil-based radio-opaque contrast agent indicated for:
Contraindications
LIPIODOL® is contraindicated in patients with hypersensitivity to LIPIODOL®, hyperthyroidism, traumatic injuries, recent hemorrhage or bleeding.
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
For more information, see Full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Reimbursement Information*
For further assistance, please contact For further assistance, please contact LIPIODOL® Reimbursement Support at 1-855-368-2736, Monday–Friday, 7 am–7 pm ET
Lipiodol® (Ethiodized Oil) Injection is a registered trademark of Guerbet LLC or its affiliates and is available by prescription only.
References
1. Miszczuk M, Chapiro J, Geschwind JF, Thakur V, Schlachter T; Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Translational Oncology, Volume 13, Issue 3March 2020 Article 100742
2. Key Statistics About Liver Cancer, 2020; https://www.cancer.org/cancer/liver-cancer/about/what-is-key-statistics.html
4. Rizvi S. et al, Is post-Lipiodol CT Better Than IV Contrast CT Scan for Early Detection of HCC? A Single Liver Transplant Center Experience, Transplant. Proc. 2006; 38: 2993-2995
5. Gonsalves C.F., Chemoembolization of hepatic malignancy, Abdom. Imaging, 2009; 34:557-65
6. Pourgholami M. et al,. Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in Lipiodol, Cancer Letters, 2004; 207
7. Bruneton JN. et al., Hepatic Intraarterial Lipiodol: Technique, Semiologic Patterns, and Value for Hepatic Tumors, Gastrointest. Radiol., 1988,13:45-51
8. Ngan H. et al. Lipiodol computerized tomography: how sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? Br. J. Radiol.,1990; 63: 771-775
GU05201138